ImmuPharma (STU:25I) Days Payable : 0.00 (As of Jun. 2023)

View and export this data going back to 2012. Start your Free Trial

What is ImmuPharma Days Payable?

ImmuPharma's average Accounts Payable for the six months ended in Jun. 2023 was €1.52 Mil. ImmuPharma's Cost of Goods Sold for the six months ended in Jun. 2023 was €0.00 Mil.

The historical rank and industry rank for ImmuPharma's Days Payable or its related term are showing as below:

STU:25I's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.78
* Ranked among companies with meaningful Days Payable only.

ImmuPharma's Days Payable stayed the same from Jun. 2022 (0.00) to Jun. 2023 (0.00).

ImmuPharma Days Payable Historical Data

The historical data trend for ImmuPharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuPharma Days Payable Chart

ImmuPharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Payable

Get a 7-Day Free Trial

ImmuPharma Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of ImmuPharma's Days Payable

For the Biotechnology subindustry, ImmuPharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuPharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuPharma's Days Payable distribution charts can be found below:

* The bar in red indicates where ImmuPharma's Days Payable falls into.

ImmuPharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

ImmuPharma's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (1.36	+	1.231)	/	2 )	/	0	*	365
=	1.2955					/	0	*	365
=	N/A

ImmuPharma's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

	Days Payable (Q: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (1.231	+	1.808)	/	2 )	/	0	*	365 / 2
=	1.5195					/	0	*	365 / 2
=	N/A

ImmuPharma Days Payable Related Terms

Thank you for viewing the detailed overview of ImmuPharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuPharma (STU:25I) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuPharma PLC (STU:25I) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

IMM.GB:UK IMM:UK

Address

One Bartholomew Close, London, GBR, EC1A 7BL

Website

https://www.immupharma.co.uk

ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus and a life-threatening autoimmune disease.

ImmuPharma (STU:25I) Headlines

No Headlines